- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Utility of Fedratinib in Myelofibrosis
Authors
Keywords
-
Journal
OncoTargets and Therapy
Volume Volume 14, Issue -, Pages 4509-4521
Publisher
Informa UK Limited
Online
2021-08-20
DOI
10.2147/ott.s267001
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome
- (2021) Francesca Palandri et al. CANCER
- Next Generation Therapeutics for the Treatment of Myelofibrosis
- (2021) Douglas Tremblay et al. Cells
- Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure
- (2020) Claire N. Harrison et al. AMERICAN JOURNAL OF HEMATOLOGY
- Fedratinib Induces Spleen Responses and Reduces Symptom Burden in Patients with Myeloproliferative Neoplasm (MPN)-Associated Myelofibrosis (MF) and Low Platelet Counts, who were Either Ruxolitinib-Naïve or were Previously Treated with Ruxolitinib
- (2020) Claire N Harrison et al. BLOOD
- Single-cell analysis based dissection of clonality in myelofibrosis
- (2020) Elena Mylonas et al. Nature Communications
- Comprehensive review of Wernicke encephalopathy: pathophysiology, clinical symptoms and imaging findings
- (2020) Yoshiaki Ota et al. JAPANESE JOURNAL OF RADIOLOGY
- Patient characteristics and outcomes after ruxolitinib discontinuation in patients with myelofibrosis
- (2020) John Mascarenhas et al. JOURNAL OF MEDICAL ECONOMICS
- A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy
- (2019) Naseema Gangat et al. Blood Cancer Journal
- Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model
- (2019) Rangit R. Vallapureddy et al. Blood Cancer Journal
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
- (2019) Alexander E. Perl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic Effects of JAK1/2 Inhibition in Patients with Myeloproliferative Neoplasms
- (2019) Manali Sapre et al. Scientific Reports
- Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis
- (2019) Francesca Palandri et al. CANCER
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms
- (2018) Maria Kleppe et al. CANCER CELL
- BET’ing on Dual JAK/BET Inhibition as a Therapeutic Strategy for Myeloproliferative Neoplasms
- (2018) Qingfei Jiang et al. CANCER CELL
- Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients with Myelofibrosis: A Case Series
- (2018) Aaron Gerds et al. Clinical Lymphoma Myeloma & Leukemia
- Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis
- (2018) Hans Michael Kvasnicka et al. Journal of Hematology & Oncology
- Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management
- (2018) Ayalew Tefferi AMERICAN JOURNAL OF HEMATOLOGY
- Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses
- (2017) Srdan Verstovsek et al. Journal of Hematology & Oncology
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study
- (2017) Claire N Harrison et al. Lancet Haematology
- Does ruxolitinib prolong the survival of patients with myelofibrosis?
- (2016) Francisco Cervantes et al. BLOOD
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial
- (2016) H. K. Al-Ali et al. HAEMATOLOGICA
- Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm
- (2015) Jasmanda Wu et al. Cancer Epidemiology
- JAK2 inhibition has different therapeutic effects according to myeloproliferative neoplasm development in mice
- (2015) Franck Debeurme et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis
- (2015) A Pardanani et al. Blood Cancer Journal
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis
- (2015) Animesh Pardanani et al. JAMA Oncology
- Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis
- (2014) A. Tefferi et al. BLOOD
- CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
- (2014) A Tefferi et al. LEUKEMIA
- Dual kinase-bromodomain inhibitors for rationally designed polypharmacology
- (2014) Pietro Ciceri et al. Nature Chemical Biology
- A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers
- (2013) Meng Zhang et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera
- (2012) A. Mullally et al. BLOOD
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
- (2011) Animesh Pardanani et al. JOURNAL OF CLINICAL ONCOLOGY
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor Cells
- (2010) Ann Mullally et al. CANCER CELL
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
- Constitutive JunB expression, associated with the JAK2 V617F mutation, stimulates proliferation of the erythroid lineage
- (2008) B da Costa Reis Monte-Mór et al. LEUKEMIA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started